TherapeuticsMD (NASDAQ:TXMD) was upgraded by stock analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a report released on Tuesday.

Several other research firms also recently weighed in on TXMD. Oppenheimer set a $10.00 price target on TherapeuticsMD and gave the stock a “buy” rating in a research note on Thursday, August 17th. Jefferies Group restated a “buy” rating and issued a $15.00 price target on shares of TherapeuticsMD in a research note on Friday, September 8th. Noble Financial restated a “buy” rating on shares of TherapeuticsMD in a research note on Thursday, November 30th. Deutsche Bank set a $10.00 price target on TherapeuticsMD and gave the stock a “buy” rating in a research note on Tuesday, August 22nd. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $33.00 price target on shares of TherapeuticsMD in a research note on Monday, September 4th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $15.00.

Shares of TherapeuticsMD (NASDAQ:TXMD) traded up $0.16 during trading hours on Tuesday, hitting $6.42. The stock had a trading volume of 2,934,700 shares, compared to its average volume of 2,891,053. TherapeuticsMD has a 12-month low of $3.50 and a 12-month high of $8.30.

TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings results on Monday, November 6th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.03. The company had revenue of $4.42 million for the quarter, compared to the consensus estimate of $5.36 million. TherapeuticsMD had a negative return on equity of 65.16% and a negative net margin of 457.00%. The firm’s quarterly revenue was down 19.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.13) EPS. research analysts expect that TherapeuticsMD will post -0.37 earnings per share for the current fiscal year.

In other TherapeuticsMD news, Director Tommy G. Thompson bought 5,000 shares of the business’s stock in a transaction on Friday, December 8th. The shares were acquired at an average cost of $6.21 per share, for a total transaction of $31,050.00. Following the purchase, the director now owns 3,555 shares in the company, valued at approximately $22,076.55. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 23.92% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the business. Candriam Luxembourg S.C.A. boosted its stake in TherapeuticsMD by 10.4% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 530,000 shares of the company’s stock valued at $2,804,000 after purchasing an additional 50,000 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its stake in shares of TherapeuticsMD by 10.8% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 694,167 shares of the company’s stock worth $3,659,000 after buying an additional 67,855 shares during the last quarter. Swiss National Bank boosted its stake in shares of TherapeuticsMD by 12.3% in the 3rd quarter. Swiss National Bank now owns 289,800 shares of the company’s stock worth $1,533,000 after buying an additional 31,800 shares during the last quarter. Raymond James Financial Services Advisors Inc. boosted its stake in shares of TherapeuticsMD by 293.0% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 112,900 shares of the company’s stock worth $595,000 after buying an additional 84,170 shares during the last quarter. Finally, Stifel Financial Corp boosted its stake in shares of TherapeuticsMD by 377.9% in the 2nd quarter. Stifel Financial Corp now owns 2,052,030 shares of the company’s stock worth $10,820,000 after buying an additional 1,622,668 shares during the last quarter. Institutional investors and hedge funds own 73.76% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/12/therapeuticsmd-txmd-rating-increased-to-sell-at-bidaskclub.html.

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.